February 1, 2019Open Access

Adherence to recommended clinical guidelines in extensive disease small-cell lung cancer across the US, Europe, and Japan

Key Points

Key points are not available for this paper at this time.

Abstract

In contrast to treatment guidelines, a significant proportion of real-world PR patients were re-challenged with a 2L platinum-based therapy, while conversely, many PS patients did not receive platinum-based therapies in 2L. This study highlights a lack of a consistent paradigm for 2L ED-SCLC treatment, limited therapeutic options, and an unmet need among SCLC patients.

Demander à l'IA

Bookmark

View Full Paper

Cite This Study

DiBonaventura et al. (Fri,) studied this question.

synapsesocial.com/papers/69d9d9df0d540cafc5837b5f https://doi.org/https://doi.org/10.2147/tcrm.s183216

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Twenty Years of Phase III Trials for Patients With Extensive-Stage Small-Cell Lung Cancer: Perceptible Progress1999 · 348 citations
2Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small-Cell Lung Cancer2002 · 1,374 citations
31969 Cancer Facts and Figures1968 · 8,866 citations
4Initial Evaluation of the Patient With Lung Cancer: Symptoms, Signs, Laboratory Tests, and Paraneoplastic Syndromes2007 · 215 citations
5Patient Count Projections for Advanced Melanoma by Line of Therapy and Other Clinical Characteristics in EU Countries: Results from The UK, Germany, France, Italy and Spain (EU-5)2014 · 2 citations

Demander à l'IA

Bookmark

View Full Paper